Mereo BioPharma (MREO) Payables (2017 - 2026)

Mereo BioPharma (MREO) has reported Payables for 10 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.

• Quarterly Payables rose 10.33% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (up 10.33% YoY) and the FY2025 annual result came in at $1.3 million, down 83.29% from the prior year.
• Payables advanced to $3.2 million in Q1 2026 per MREO's latest filing, from $1.3 million in the prior quarter.
• Over the last five years, Payables for MREO reached as high as $16.6 million in Q4 2022 and fell as low as $879000.0 in Q3 2025.
• A 5-year average of $5.4 million and a median of $3.6 million in 2022 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables jumped 393.14% — and 2025, when it plunged 87.96%.
• Year by year, Payables stood at $16.6 million in 2022, then slumped by 85.88% to $2.3 million in 2023, then soared by 239.94% to $8.0 million in 2024, then sank by 83.29% to $1.3 million in 2025, then surged by 142.01% to $3.2 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $3.2 million, $1.3 million, and $879000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.